威尔药业实控人方拟减持去年套现3818万元 A股募5.9亿

Summary of Key Points Core Viewpoint - 威尔药业 announced a plan for a concentrated auction reduction of shares by its employee stockholding platform, 舜泰宗华, which holds approximately 6.49% of the company's total shares [1]. Group 1: Share Reduction Plan - 舜泰宗华 plans to reduce its holdings by up to 446,340 shares, representing no more than 0.33% of the total share capital, between March 23 and April 10, 2026 [1]. - The estimated value of the planned reduction is approximately 12.30 million yuan, based on the closing price of 27.55 yuan per share on February 26 [1]. Group 2: Shareholding Structure - 舜泰宗华 is managed by 吴仁荣, who is also an executive partner, and is considered a concerted actor with 高正松 and 陈新国 [2]. - As of the latest announcement, 舜泰宗华 has reduced its holdings by 1,354,291 shares, with a total remaining of 8,788,699 shares [2]. Group 3: Company Financials and History - 威尔药业 was listed on the Shanghai Stock Exchange on January 30, 2019, with an initial public offering of up to 16.67 million shares at a price of 35.50 yuan per share, raising a total of approximately 591.67 million yuan [2]. - The net proceeds from the IPO were approximately 538.50 million yuan, allocated for the establishment of a production base for injectable drug excipients and to supplement working capital [2]. Group 4: Bond Issuance Update - The Shanghai Stock Exchange announced the termination of the review for 威尔药业's issuance of convertible bonds to unspecified investors, which was intended to raise up to 306 million yuan [3]. - The underwriting institution for the bond issuance was 中国银河证券, with representatives段然 and 夏沛沛 [3].